Errata (DOI:10.1016/j.juro.2008.05.009);Finnish Multicenter Study Comparing Intermittent to Continuous Androgen Deprivation for Advanced Prostate Cancer: Interim Analysis of Prognostic Markers Affecting Initial Response to Androgen Deprivation

Journal of Urology

Volumn 180, Issue 3, 2008, Pages 915-920

  Salonen, Arto J ^a   Viitanen, Jouko ^a   Lundstedt, Seppo ^a   Ala Opas, Martti ^a   Taari, Kimmo ^a   Tammela, Teuvo L J ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

prostatic neoplasms; testosterone; tumor burden

Indexed keywords

ALKALINE PHOSPHATASE; CYPROTERONE ACETATE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; HORMONE SENSITIVITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; TRANSURETHRAL RESECTION; TREATMENT RESPONSE;

EID: 48849104783     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.11.001     Document Type: Erratum

References (21)

1. Gleave M., Goldenberg S.L., Bruchovsky N., and Rennie P. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer Prostatic Dis 1 (1998) 289
2. Kurek R., Renneberg H., Lubben G., Kienle E., and Tunn U.W. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 35 (1999) 27
3. Albrecht W., Collette L., Fava C., Kariakine O.B., Whelan P., Studer U.E., et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol 44 (2003) 505
4. Petrylak D.P. The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology 65 (2005) 3
5. Crook J.M., Szumacher E., Malone S., Huan S., and Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology 53 (1999) 530
6. Rashid M.H., and Chaudhary U.B. Intermittent androgen deprivation therapy for prostate cancer. Oncologist 9 (2004) 295
7. de Leval J., Boca P., Youssef E., Nicolas H., Jeukenne M., Seidel L., et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 1 (2002) 163
8. Cury F.L., Souhami L., Rajan R., Tanguay S., Gagnon B., Duclos M., et al. Intermittent androgen ablation in patients with biochemical failure after pelvic radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 64 (2006) 842
9. Goldenberg S.L., Bruchovsky N., Gleave M.E., Sullivan L.D., and Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45 (1995) 839
10. Bouchot O., Lenormand L., Karam G., Prunet D., Gaschignard N., Malinovsky J.M., et al. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 38 (2000) 543
11. Rambeaud J. Intermittent complete androgen blockade in metastatic prostate cancer. Eur Urol 35 (1999) 32
12. Van Cangh P.J., Tombal B., and Gala J.L. Intermittent endocrine treatment. World J Urol 18 (2000) 183
13. Cleary P.D., Morrissey G., and Oster G. Health-related quality of life in patients with advanced prostate cancer: a multinational perspective. Qual Life Res 4 (1995) 207
14. Patterson S.G., Balducci L., and Pow-Sang J.M. Controversies surrounding androgen deprivation for prostate cancer. Cancer Control 9 (2002) 315
15. Sato N., Akakura K., Isaka S., Nakatsu H., Tanaka M., Ito H., et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 64 (2004) 341
16. Noble R.L. Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res 37 (1977) 82
17. Klotz L.H., Herr H.W., Morse M.J., and Whitmore Jr. W.F. Intermittent endocrine therapy for advanced prostate cancer. Cancer 58 (1986) 2546
18. Grossfeld G.D., Small E.J., Lubeck D.P., Latini D., Broering J.M., and Carroll P.R. Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology 58 (2001) 56
19. Massengill J.C., Sun L., Moul J.W., Wu H., McLeod D.G., Amling C., et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169 (2003) 1670
20. Chen S.S., Chen K.K., Lin A.T., Chang Y.H., Wu H.H., and Chang L.S. The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int 89 (2002) 710
21. Prapotnich D., Fizazi K., Escudier B., Mombet A., Cathala N., and Vallancien G. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 43 (2003) 233